This site is intended for an Australian audience. To view your own country’s website, if available. Please select your country from the list provided.
Close
Close

Supporting you through the menopause

Close
Close

Overactive bladder could be impacting a woman’s life

Close

Our diverse portfolio helps us deliver on our commitment to Women's Health

Close

Zoely Portal

Findings from the ProE2 study – the largest combined oral contraceptive safety study yet conducted

Obstetrician and Gynaecologist, A/Prof. Gino Pecoraro translates the findings of the post authorisation safety study, PRO-E2, to everyday clinical practice detailing the real-world evidence and ongoing safety monitoring that are increasingly important to the decisions clinicians make for their patients on a daily basis. Click the play button below to view the webinar recording.

Request to speak with a Theramex Key Account Manager

I would like to receive more information on (select below):

PBS Information: This product is not listed on the PBS

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING. Full Product Information is available from Medical Information: 1800 THERAMEX (1800 843 726) or online at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-03366-3

Minimum product information: Zoely® 2.5mg Nomegestrol acetate / 1.5mg estradiol (as hemihydrate). Indication: Oral contraception. Contraindications: Presence or risk of the following: venous thromboembolism (VTE); arterial thromboembolism (ATE); severe hepatic disease as long as liver function values have not returned to normal; liver tumours (benign or malignant); meningioma. History of migraine with focal neurological symptoms, pancreatitis or a history thereof if associated with severe hypertriglyceridaemia. Known or suspected: sex steroid-influenced malignancies (e.g., of the genital organs or the breasts); pregnancy; hypersensitivity to any of the active substances of ZOELY® or to any of the excipients. Precautions: A medical history/examination prior to initiation. Exclude pregnancy before use. Medical check-ups during use. If any of conditions/risk factors below is present, benefits of the use of ZOELY® should be weighed against possible risks and discussed before using ZOELY®. Risk of VTE, risk of ATE, Neoplasms, Meningioma, Hepatitis C, hypertriglyceridaemia, hypertension, jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham’s chorea; herpes gestationis; otosclerosis related hearing loss; (hereditary) angioedema, acute or chronic disturbances of liver function, diabetics, Crohn’s disease, chloasma and galactose intolerance. Interactions: Hepatic metabolism, antibiotics, others: ombitasvir/paritaprevir/ritonavir. Adverse Events: Acne, abnormal withdrawal bleeding, decreased libido, depression, migraine, nausea, metrorrhagia, menorrhagia, breast pain, pelvic pain, weight increase, see PI for others. Dosage: One tablet daily at about the same time. Take with some liquid as needed, and in the order as directed on the package. Based on product information last amended 25th August, 2025.

Sponsored in Australia by Theramex Australia Pty Ltd, ABN 37 623 186 845, 60 Margaret Street, Sydney, NSW 2000. www.theramex.com.au; Date of preparation, September 2025; ZOELY_AU_EN_24429_v1

Close

This site is intended for health care professionals only

Please enter your AHPRA registration number above to access information on this page.

By submitting this request, I confirm I am a registered health care professional. Theramex will not disclose your personal information to anyone other than contractors who provide services to us or unless compelled or permitted by law to do so. To view our full privacy policy please refer to our global website www.theramex.com